Generate Biomedicines Inc (NASDAQ:GENB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $25.40.

GENB has been the topic of a number of recent analyst reports. Piper Sandler assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective on the stock. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. The Goldman Sachs Group assumed coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target for the company. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating on the stock. Finally, Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Generate Biomedicines Trading Down 2.2%

NASDAQ GENB opened at $15.87 on Thursday. The company has a 50 day simple moving average of $14.43. The stock has a market capitalization of $2.03 billion and a price-to-earnings ratio of -14.83. Generate Biomedicines has a one year low of $11.00 and a one year high of $18.18.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.